go-v.orgdoi

Correction: Fish oil: what the prescriber needs to know

Leslie G. Cleland, Michael J. James, Susanna Proudman · Arthritis Research & Therapy · 2006

  • DOI 10.1186/ar1981
  • Publisher BioMed Central
  • Type article
  • Issued 2006

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Arthritis Research & Therapy · BioMed Central · article · 2006

Abstract

It has been brought to our attention that there were a number of typographical errors in one section of our recent article [1] published in December 2005. All corrections apply to the section entitled, 'Biochemical rationale; Eicosanoids: cyclo-oxygenase pathway'. The second paragraph should read: The usual substrate for the COX isozymes is the n6 LC PUFA arachidonic acid (AA; C20:4n-6). Eicosapentaenoic acid (EPA; C20:5n-3), which is present in fish oil, differs from AA only by the presence of its n3 bond (Fig. 1).

The last sentence of the third paragraph should read: Thus, the net effect of fish oil is to reduce the production of proinflammatory and pro-thrombotic eicosanoids (PGE2 and TXA2, respectively) but not the vascular patency factor prostacyclin (PGI2; Fig. 2). Finally, the first 20-Carbon fatty acid homologue pictured in Figure 1 (C20:3 n-9) is eicosatrienoic acid, rather than oleic acid.

Open the resolved locator · 10.1186/ar1981

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 04:10 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://link.springer.com/article/10.1186/ar1981
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.